KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) FCF Margin (2017 - 2025)

Teva Pharmaceutical Industries' FCF Margin history spans 9 years, with the latest figure at 21.57% for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 619.0% year-over-year to 21.57%, compared with a TTM value of 6.65% through Dec 2025, up 173.0%, and an annual FY2025 reading of 6.65%, up 212.0% over the prior year.
  • FCF Margin for Q4 2025 was 21.57% at Teva Pharmaceutical Industries, up from 5.2% in the prior quarter.
  • The five-year high for FCF Margin was 23.89% in Q4 2023, with the low at 13.94% in Q1 2021.
  • Average FCF Margin over 5 years is 4.83%, with a median of 4.17% recorded in 2025.
  • Year-over-year, FCF Margin crashed -1800bps in 2021 and then soared 1632bps in 2024.
  • Tracing TEVA's FCF Margin over 5 years: stood at 7.39% in 2021, then soared by 190bps to 21.4% in 2022, then increased by 12bps to 23.89% in 2023, then tumbled by -36bps to 15.38% in 2024, then surged by 40bps to 21.57% in 2025.
  • Per Business Quant, the three most recent readings for TEVA's FCF Margin are 21.57% (Q4 2025), 5.2% (Q3 2025), and 3.14% (Q2 2025).